Study of a new drug for anemia caused by chemotherapy
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new medicine, SSS06, to help people whose red blood cell count drops too low after chemotherapy. It aims to reduce fatigue and other symptoms of anemia, making it easier to continue cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of cancer that is not in the bone marrow (like leukemia).
- Your hemoglobin (a part of red blood cells) is 100 or lower, and it dropped by at least 10 after starting chemo.
- You have enough iron in your body (ferritin and transferrin levels meet the study's minimum).
- You weigh at least 40 kg (about 88 pounds).
- You are able to care for yourself but may need some help (ECOG score 1 or 2).
- You are expected to live at least 6 more months.
- You plan to continue chemotherapy for at least 8 more weeks.
- You agree to use birth control if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication (AND017) to see if it can safely help raise hemoglobin levels in people with anemia caused by chemotherapy. If you have cancer (not leukemia) and are currently on chemo, this trial might help manage your anemia and improve your energy.
This study tests a new medication (SAL-0951) for treating low red blood cell counts (anemia) caused by chemotherapy in people with certain types of cancer that are not curable. It may help improve energy and reduce the need for blood transfusions.
This trial is testing a new medicine called HS-20106 to see if it can improve anemia (low red blood cells) for people with certain types of MDS. If it works, it might reduce the need for blood transfusions.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial tests an investigational drug, TAK-226, for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The study aims to see if the drug can help improve blood counts and reduce the need for red blood cell transfusions.
This trial tests a new pill, AND017, for people with cancer who have low red blood cell counts (anemia) and are not getting chemotherapy. The goal is to see if the drug helps raise hemoglobin levels and reduce fatigue.
Hear when a new Chemotherapy-induced Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.